The Rise of Chinese Biotechs and the Global CRO Question

What’s Actually Driving the Rise

Rather than a single catalyst or event driving this growth, there is a handful of structural changes working together:

• Policy reform. The CDE (Center for Drug Evaluation) reforms, beginning in 2015, rebuilt China’s regulatory review system to align more closely with international standards, cutting approval timelines and raising the evidentiary bar.
• Capital reinforcement. Hong Kong’s Chapter 18A listing rules, introduced to let pre-revenue biotechs go public, opened new funding pathways alongside a maturing licensing-out market and mainland exchanges.
• Talent return. Scientists who trained and worked at Western pharma companies are coming home, bringing global R&D standards with them, while domestic engineering talent has grown in parallel.
• A complete industry chain. China now has efficient, end-to-end R&D infrastructure (discovery through manufacturing through clinical execution), which compresses development timelines.
• Market scale. A large domestic patient population creates both demand and faster recruitment.
• A pivot from generics to first-in-class. Chinese biotechs are increasingly building novel pipelines rather than following approved mechanisms.

None of these alone explains the ASCO moment. The ecosystem itself has shifted from manufacturing capacity to genuine innovation capacity, which is exactly why global partners and regulators are paying closer attention.

That capability shift creates a new kind of pressure: being able to compete globally isn’t the same as being ready to run a trial outside China.

4 Critical Decision Points Before the First Global Trial

Every biotech faces the same four decisions before their first trial outside China, whether or not they name them explicitly:

1. Ultimate targeted market: Where does this compound ultimately need approval and commercial reach?

Common mistake: Teams like to approach global main countries first, even when a smaller, faster market would validate the asset sooner.

2. Regulatory requirement: What does each relevant authority require, and in what sequence?

Common mistake: Teams run into a lack of key material for regulatory submission and approval because documentation wasn’t prepared early enough.

3. Time efficiency: How should the program be sequenced to protect runway?

Common mistake: Teams end up with a slow CRO tasked with meeting an aggressive timeline, but the pace mismatch can derail the program’s runway.

4. Cost effectiveness: What does the trial actually cost to run well, not just to start?

Common mistake: Poor control of budget leads to multiple change orders, which turns a planned trial into a series of expensive amendments.

None of the missteps are catastrophic on their own. But they compound. A slow regulatory package delays site activation; a slow CRO burns runway budgeted for the next phase. The fix, in every case, is deciding these four things deliberately and early, not defaulting to the most familiar answer.

The right partner shapes market sequencing, keeps documentation ahead of submission deadlines, and protects both timeline and budget at once. That’s exactly why CRO selection is often the highest-leverage decision a team makes this early — see why early CRO choice is critical to accelerating clinical program delivery.

CRO choice shapes how well a team executes on these decisions, but the market decision still has to be made on its own terms. The right answer to those four decisions depends on the program, and no single market fits every case. But one option performs consistently well against all four, which is why it comes up so often in these conversations: Australia.

How Australia’s Mature R&D Ecosystem Supports More Than Just Early Phase Work

The R&D tax incentive (up to 43.5% back on eligible trial expenditure) and the absence of an IND-equivalent requirement are the two facts most companies already know about Australia. What tends to surprise most teams is something less quantifiable: how mature the ecosystem actually is.

Because Australia’s ecosystem is genuinely mature, the trial data it produces is fully accepted by major global regulatory authorities, including the TGA, FDA, and EMA. For first-in-human healthy volunteer trials specifically, Australia consistently offers one of the shortest timeframes anywhere in the world — 5-6 week study startup.

Speed and data quality only matter if they translate into results a team can act on later: licensing deals, regulatory approvals, follow-on funding, etc. For example, when a company developing a pain therapeutic noted global registration as the explicit goal from the outset, they were able to build a program specifically for international registration from the first protocol conversation through Avance Clinical’s GlobalReady framework. The team efficiently optimized their study design around that end goal, hitting their trial targets, and drawing interest from a global pharmaceutical company. The compound was ultimately licensed out in a billion-dollar deal.

Global registration doesn’t guarantee that outcome. By building a strategic development pathway from the earliest phase, instead of retrofitting a domestic-first trial later, biotech teams can keep every subsequent decision aligned instead of creating multidisciplinary rework.

Where the Momentum Is Now

A few signals point to where innovators are headed next to set their products up for global regulatory and market success:

• Oncology continues to be the dominant therapeutic area globally, and increasingly the one where Chinese-originated science is competing directly, as ASCO just demonstrated.
• A growing number of U.S. biotechs are establishing entities in China specifically to run clinical trials in Asia as part of their global programs.
• As Chinese-originated science advances toward global markets, Australia remains a go-to location for first-in-human healthy volunteer trials.

Takeaway: Australia isn’t a shortcut; It’s a smart start. Teams get clean, globally accepted data faster, at a cost structure that lets them do more with the capital they have.

The HARMONi-6 trial shows that Chinese-originated science can compete at the highest level. The operational side of that story (deciding where and how that first trial outside China gets built) has to happen at the earliest phase, or the risk of costly late-phase setbacks compounds.

If you’re planning your first trial outside China, talk to an expert at Avance Clinical about building a program designed for global registration from the earliest R&D phase onward.

About the Author